Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians in the U.S. who Treat Patients with Myelodysplastic Syndromes (MDS)

Articles with lock require a subscription to GLG News | Request a free trial
December 1, 2008
Avastin Raises Risk of Clots: New News?
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.
November 24, 2008
Avastin and clots? News to me. Black box warning? Why?
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: GLG Expert Contributor
The exact quote is " Avastin, could raise the risk of blood clots by about 12 percent."
November 24, 2008
This strategy is running out of steam.
Analysis of: How a Drug Maker Tries to Outwit Generics | online.wsj.com
Author: GLG Expert Contributor
These strategies are running out of steam as insurers, and even the general public, are catching on.  Most insurers will only pay for generic modafanil, and these new versions will not sell as much as they would have even 5 years ago.  The abuse potential of the drug may help, as brand-name...
November 24, 2008
GSK's Promacta for ITP: a winner1
Analysis of: PROMACTA (Brand Name Drug) FDA approval 11/20/08 | www.accessdata.fda.gov
Author: GLG Expert Contributor
An oral agent that can be used in patients with ITP that have become refractory to steroids, splenectomy and various immunologic manipulations.
November 19, 2008
Vandetanib (Astra Zeneca): too long at the "Fair?"
Analysis of: Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
A VEGF inhibitor that appears to work well with chemo in non small cell lung carcinoma.
November 17, 2008
Erbitux in Lung Ca- now to predict who will get the skin rash.
Analysis of: Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months | www.pipelinereview.com
Author: GLG Expert Contributor
"New data from pivotal FLEX study reveal that patients treated with Erbitux who develop early skin rash show median overall survival of 15 months (p<0.001)" This is the trial that showed Erbitux + chemo prolonged survival minimally when compared to chemo alone. Now we know the ones who develop a...
November 11, 2008
Roche's Tarceva offers a competitor to Lilly's Alimta
Analysis of: Roche Says Tarceva Data Promising | online.wsj.com
Author: GLG Expert Contributor
Tarceva can maintain a remission in non small cell lung cancer after initial therapy with other agents. Just like Lilly's Alimta
November 11, 2008
Increased use of Zevalin, Bayer ( & by osmosis Bexxar, GSK) in low grade lymphomas
Analysis of: Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma | jco.ascopubs.org
Author: GLG Expert Contributor
Addition of Zevalin after a CR or PR in low grade, follicular lymphomas adds to CR rates and improves time to progression. The implication is that this will result in improved survivals.
November 10, 2008
Is Pharma's Head in the Sand??
Analysis of: Pharma need not worry too much about President Obama | www.pharmatimes.com
Author: GLG Expert Contributor
The implication is that our new chief executive has "bigger fish to fry" than attaching drug costs??
November 6, 2008
GSK to cut sales force , but......
Analysis of: Glaxo Plans 12% Reduction in Its U.S. Drug Sales Force | online.wsj.com
Author: GLG Expert Contributor
"As part of the restructuring, the company plans to group its sales staff around specific treatment areas" including oncology, probably

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 535

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203